Clinical trials: Esophagogastric Junction Disorder
Gastric Cancer
CKD-702 Plus Irinotecan in Gastric Cancer
CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR).
- Trial name
- NCT05750290
- Testing
- CKD-702 in combination with irinotecan
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- National Cancer Center, Korea
Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma
Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France
A study to estimate the overall survival in real-life conditions in France of adult participants treated with nivolumab in combination with chemotherapy as first-line treatment for gastric and gastroesophageal junction cancer.
- Conditions
- Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- METAGIO (NCT06504615)
- Testing
- nivolumab + chemotherapy
- Where
- 2 sites in France
- Volunteers
- 208 people
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer
Neoadjuvant TACiE in Locally Advanced Gastric Cancer
This is a prospective, single-center, single-arm, phase 2 trial to evaluate the feasibility and safety of neoadjuvant transcatheter infusion and embolism (TACiE) in patients with locally advanced adenocarcinoma of stomach and…
- Trial name
- NCT05346874
- Testing
- Oxaliplatin, Teysuno, Transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shanghai Zhongshan Hospital
Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
The purpose of the study is to understand whether study drugs domvanalimab and zimberelimab are safe and effective in combination with standard chemotherapy for patients with operable cancer of the esophagus, stomach, or…
- Trial name
- NCT07283848
- Testing
- Zimberelimab, Domvanalimab, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Esophageal Cancer, Gastric Cancer
Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006081
- Testing
- Bryostatin-1, Paclitaxel (Taxol)
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Adebrelimab, Esophageal Cancer
Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma
The goal of this prospective, open-label, single-center clinical study is to learn about the efficacy and safety of aderbelimab combined with chemotherapy in the perioperative treatment of esophageal and esophagogastric junction…
- Conditions
- Adebrelimab, Esophageal Cancer, Perioperative Period
- Trial name
- NCT06198465
- Testing
- adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Xijing Hospital
Esophageal Cancer, Gastric Cancer
Spanish Registry of Esophagogastric Cancer
This study aims to development of a database through a web page for epidemiological and clinical research purposes that is accessible to members of the AGAMENON - SEOM group that guarantees a rigorous collection, exploitation and…
- Trial name
- AGAMENON (NCT04958720)
- Testing
- Surgery, Chemotherapy, anti-targeted agents and immunotherapy, Radiotherapy
- Where
- 38 sites in Spain
- Volunteers
- 10,000 people
- Sponsor
- Fundación Sociedad Española de Oncologia Médica
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of KK2269 in Adult Participants With Solid Tumors
This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06266299
- Testing
- KK2269, Docetaxel
- Where
- 32 sites in United States, Japan
- Volunteers
- 83 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Gastric Cancer
Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer
For locally advanced gastric cance, neoadjuvant chemotherapy can increase the resectability of tumor, and finally improve the long-term survival.
- Trial name
- NCT04367025
- Testing
- Camrelizumab, Oxaliplatin, S1
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Chinese PLA General Hospital
Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Gastric/GEJ adenocarcinoma, which is one of the major leading causes of cancer-related deaths worldwide, is a global challenge to human health.
- Trial name
- NCT06177041
- Testing
- M108 monoclonal antibody, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 486 people
- Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
Gastric Cancer, Gastroesophageal Junction Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated Chinese adults with gastric and gastroesophageal…
- Trial name
- NCT04882241
- Testing
- Pembrolizumab, Cisplatin, Capecitabine
- Where
- 20 sites in China
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction
NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)
This is a multicentre phase III open-labelled, randomised controlled trial. Eligible patients will be randomised in a 1:1 fashion between neoadjuvant and adjuvant chemotherapy (Investigator's choice modified MAGIC (ECF/ECX or…
- Conditions
- Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction, Oesophageal Tumours, Junctional Tumours
- Trial name
- NCT01726452
- Testing
- Epirubicin, Cisplatin / Oxaliplatin, 5 Flourouracil/ Capecitabine
- Where
- 29 sites in Denmark, France and 3 more
- Volunteers
- 377 people
- Sponsor
- Cancer Trials Ireland
Stomach Neoplasms, Esophageal Neoplasms
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
This phase II trial studies how well combination chemotherapy works in treating patients with advanced stomach, gastroesophageal, or esophageal cancer.
- Trial name
- FOLFIRINOX (NCT01928290)
- Testing
- Irinotecan, Trastuzumab, Oxaliplatin
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Washington University School of Medicine
Gastric Cancer, HER2 + Gastric Cancer
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
This study is a prospective, umbrella-design, Phase II clinical trial. Eligible participants with advanced or metastatic gastric cancer who are treatment-naïve for advanced-stage systemic therapy will undergo biomarker profiling…
- Conditions
- Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 Positive
- Trial name
- NCT06881017
- Testing
- Trastuzumab, Adebrelimab, Apatinib
- Volunteers
- 140 people
- Sponsor
- China Medical University, China
Cancer of Esophagus, Esophagogastric Junction Disorder
CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1
This is an exploratory observational biomarker study in approximately 100 eligible patients with resectable adenocarcinomas of the esophagus and gastro- esophageal junction (GEJ) type I-II (GEAC) to investigate the difference…
- Trial name
- CIRCULATE1 (NCT04455282)
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Solid Tumor, Lymphoma
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers.
- Trial name
- NCT03544723
- Testing
- Ad-p53
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MultiVir, Inc.
Colorectal Cancer, Gastric Cancer
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
This is an open, single arm, multicenter phase 2 trial in which BO-112 will be administered intratumorally in combination with intravenous pembrolizumab in patients with liver metastasis from colorectal, gastric or…
- Conditions
- Colorectal Cancer, Gastric Cancer, Oesophageal Cancer
- Trial name
- NCT04508140
- Testing
- Hepatic Biopsy, BO-112 with pembrolizumab
- Where
- 12 sites in Belgium, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Highlight Therapeutics
Gastric Cancer (Diagnosis), Gastroesophageal Junction Adenocarcinoma
TAIC FOLFOX for Locally Advanced G/GEJA
Gastric cancer is the fifth most common malignancy worldwide in terms of both incidence and mortality. The majority of cases are diagnosed at advanced stage-often presenting with severe complications such as malignant stricture…
- Trial name
- TFLAG (NCT07655024)
- Testing
- TAIC, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Stomach Neoplasms, Surgery
Quantitative Fluorescent Guided Robotic Surgery for Cancer of the Gastroesophageal Junction
The investigators also aim to use our previously described quantifying method (q-ICG), to evaluate changes in gastric perfusion, during resection of cancer in the gastroesophageal junction (GEJ) and if a change in the operative…
- Trial name
- NCT04107623
- Testing
- Indocyanine Green
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Esophageal Cancer, Gastroesophageal Junction Cancer
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Sorafenib is a drug being studied for the treatment of cancer. Sorafenib has been shown to block certain proteins on the surface of some cancer cells called "growth factor receptors." Blocking these growth factor receptors can…
- Trial name
- NCT00917462
- Testing
- Sorafenib, administered orally, CT/MRI
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center